Roche's Alecensa wins EU panel's nod against mutated lung cancer
October 13, 2017 at 08:14 AM EDT
ZURICH, Oct 13 (Reuters) - Swiss drugmaker Roche's Alecensa has been recommended for approval in Europe as a first-line treatment for mutated lung cancer, a key European Medicines Agency (ESA) experts panel said on Friday.